{"id":"W4385897815","doi":"10.1093/oncolo/oyad197","title":"Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Legend Biotech; EMD Serono; Genentech; Revolution Medicines; Flatiron Health; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Sanofi; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Pfizer; National Center for Advancing Translational Sciences; LUNGevity Foundation","keywords":"Medicine; Immunotherapy; Internal medicine; Oncology; Pembrolizumab; Lung cancer; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Cancer; Progressive disease","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007846693,0.0002662303,0.0006875664,0.000278203,0.0002648346,0.0004739512,0.000329663,0.0005037945,0.0007922333],"category_scores_gemma":[0.00157188,0.0001910121,0.0007957572,0.0003087764,0.0002592274,0.0002956486,0.000384984,0.0005937933,0.000130133],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001283634,"about_ca_system_score_gemma":0.000611266,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009614583,"about_ca_topic_score_gemma":0.002062312,"domain_scores_codex":[0.9995264,0.0001405367,0.00005049051,0.0001305168,0.00008005251,0.00007192866],"domain_scores_gemma":[0.9987699,0.0002643781,0.0005140371,0.00005290371,0.00005690373,0.0003417974],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06038128,0.002219049,0.8755058,0.0002531949,0.001474931,0.0004026385,0.00016961,0.002669432,0.003670036,0.00005974576,0.0008036984,0.0523905],"study_design_scores_gemma":[0.003957259,0.03766971,0.9491715,0.00006023245,0.001105489,0.001100078,0.0001066408,0.003911861,0.001862304,0.0001374514,0.0008926403,0.00002488361],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9991085,0.0005592016,0.00004285443,0.0000388588,0.000006112865,0.00001868887,0.00009439902,0.000003209004,0.0001282187],"genre_scores_gemma":[0.9994835,0.0001211492,0.00004342557,0.00003620596,0.00001037024,0.00001924445,0.0002180091,9.124601e-7,0.00006717294],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001283634,"threshold_uncertainty_score":0.009313464,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02275108764639615,"score_gpt":0.3174268817104426,"score_spread":0.2946757940640465,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}